Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 24;22(11):5533.
doi: 10.3390/ijms22115533.

Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach

Affiliations

Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach

Alessio Filippo Peritore et al. Int J Mol Sci. .

Abstract

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are common and devastating clinical disorders with high mortality and no specific therapy. Lipopolysaccharide (LPS) is usually used intratracheally to induce ALI in mice. The aim of this study was to examine the effects of an ultramicronized preparation of palmitoylethanolamide (um-PEA) in mice subjected to LPS-induced ALI. Histopathological analysis reveals that um-PEA reduced alteration in lung after LPS intratracheal administration. Besides, um-PEA decreased wet/dry weight ratio and myeloperoxidase, a marker of neutrophils infiltration, macrophages and total immune cells number and mast cells degranulation in lung. Moreover, um-PEA could also decrease cytokines release of interleukin (IL)-6, interleukin (IL)-1β, tumor necrosis factor (TNF)-α and interleukin (IL)-18. Furthermore, um-PEA significantly inhibited the phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation in ALI, and at the same time decreased extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38/MAPK) expression, that was increased after LPS administration. Our study suggested that um-PEA contrasted LPS-induced ALI, exerting its potential role as an adjuvant anti-inflammatory therapeutic for treating lung injury, maybe also by p38/NF-κB pathway.

Keywords: acute lung injury; cytokines; inflammation; palmitoylethanolamide; ultramicronized.

PubMed Disclaimer

Conflict of interest statement

Salvatore Cuzzocrea is a coinventor on patent WO2013121449 A8 (Epitech Group s.r.l.), which deals with methods and compositions for the modulation of amidases capable of hydrolyzing N-acylethanolamines employable in the treatment of inflammatory diseases. This invention is wholly unrelated to the present study. Moreover, Cuzzocrea is also, with Epitech Group, a coinventor on the patents EP 2 821 083, MI2014 A001495, and 102015000067344, which are unrelated to the study. The remaining authors report no conflicts of interest.

Figures

Figure 1
Figure 1
The effects of um-PEA on histological damage after LPS i.t. injection. Histological analysis was evaluated in sham (A), sham + um-PEA (B), LPS (C), LPS + um-PEA (D) groups. Lung inflammation scores were assessed from 0 to 5 points for all of the following parameters: alveolar congestion, hemorrhage, infiltration or aggregation of neutrophils in airspace or vessel wall, and thickness of alveolar wall/hyaline membrane formation (E), lung edema (W/D) (F) and MPO activity (G). Images are figurative of at least three independent experiments. Values = means ± SEM of six animals in each group; *** p < 0.001 vs. sham; ### p < 0.001 vs. LPS.
Figure 2
Figure 2
Effect of um-PEA on cell infiltration and proinflammatory cytokine expression in BALF: total cells (A); macrophages (B) and neutrophils (C); IL-6 (D); IL-1β (E); TNF-α (F) and IL-18 (G) levels in BALF. Values = mean ± SEM of six animals in each group; *** p < 0.001 vs. sham, ## p < 0.01 vs. LPS and ### p < 0.001 vs. LPS.
Figure 3
Figure 3
The presence of mast cells is indicated by toluidine blue staining: Sham (A), LPS (B), LPS + um-PEA (C); mast cell count (D) in lungs. Figures are representative of at least 3 independent experiments. Values are means SEM of 6 animals for each group; *** p < 0.001 vs. sham, ### p < 0.001 vs. LPS.
Figure 4
Figure 4
Effect of um-PEA on chymase: Sham (A), LPS (B), LPS+um-PEA (C) for image 10× magnification, and Sham (D), LPS (E), LPS+um-PEA (F) for 40× magnification in lungs. The results are expressed as % of positive pixels (G). Images are figurative of at least three independent experiments. Values = means ± SEM of six animals in each group; *** p < 0.001 vs. sham, ### p < 0.001 vs. LPS.
Figure 5
Figure 5
Effect of um-PEA on tryptase: Sham (A), LPS (B), LPS+um-PEA (C) for image 10× magnification, and Sham (D), LPS (E), LPS + um-PEA (F) for 40× magnification in lungs. The results are expressed as % of positive pixels (G). Images are figurative of at least three independent experiments. Values = means ± SEM of six animals in each group; *** p < 0.001 vs. sham, ### p < 0.001 vs. LPS.
Figure 6
Figure 6
Western blots for IKB-α, NF-kB, pJNK, pERK1/2 and p38MAPK, (A). Representative Western blots for cytoplasmic IKB-α degradation (A,B), nuclear NF-κB translocation (A,C), cytoplasmic pJNK (A,D), cytoplasmic pERK1/2 (A,E) and cytoplasmic p-p38 (A,F). A demonstrative blot of lysates (six animals/group) with a densitometric analysis for all animals is shown. The results in (BF) correspond to means ± SEM of six animals in each group; *** p < 0.01 vs. sham, ### p < 0.001 vs. LPS.

Similar articles

Cited by

References

    1. Li J., Gong X., Wang Z., Chen R., Li T., Zeng D., Li M. Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China. Virus Res. 2020;286:198043. doi: 10.1016/j.virusres.2020.198043. - DOI - PMC - PubMed
    1. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. - DOI - PMC - PubMed
    1. Sweeney R.M., McAuley D.F. Acute respiratory distress syndrome. Lancet. 2016;388:2416–2430. doi: 10.1016/S0140-6736(16)00578-X. - DOI - PMC - PubMed
    1. Pacha O., Sallman M.A., Evans S.E. COVID-19: A case for inhibiting IL-17? Nat. Rev. Immunol. 2020;20:345–346. doi: 10.1038/s41577-020-0328-z. - DOI - PMC - PubMed
    1. Robb C.T., Regan K.H., Dorward D.A., Rossi A.G. Key mechanisms governing resolution of lung inflammation. Semin. Immunopathol. 2016;38:425–448. doi: 10.1007/s00281-016-0560-6. - DOI - PMC - PubMed

MeSH terms